- Home
- ANL vs DTIL Comparison
ANL vs DTIL Comparison
Compare ANL & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- DTIL
- Stock Information
- Founded
- ANL 2004
- DTIL 2006
- Country
- ANL Cayman Islands
- DTIL United States
- Employees
- ANL N/A
- DTIL N/A
- Industry
- ANL
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- DTIL Health Care
- Exchange
- ANL Nasdaq
- DTIL Nasdaq
- Market Cap
- ANL 56.0M
- DTIL 51.6M
- IPO Year
- ANL 2023
- DTIL 2019
- Fundamental
- Price
- ANL $1.45
- DTIL $4.62
- Analyst Decision
- ANL Hold
- DTIL Strong Buy
- Analyst Count
- ANL 1
- DTIL 2
- Target Price
- ANL N/A
- DTIL $47.00
- AVG Volume (30 Days)
- ANL 6.9K
- DTIL 219.2K
- Earning Date
- ANL 08-12-2025
- DTIL 08-12-2025
- Dividend Yield
- ANL N/A
- DTIL N/A
- EPS Growth
- ANL N/A
- DTIL N/A
- EPS
- ANL N/A
- DTIL N/A
- Revenue
- ANL N/A
- DTIL $51,141,000.00
- Revenue This Year
- ANL N/A
- DTIL N/A
- Revenue Next Year
- ANL N/A
- DTIL $53.21
- P/E Ratio
- ANL N/A
- DTIL N/A
- Revenue Growth
- ANL N/A
- DTIL N/A
- 52 Week Low
- ANL $1.10
- DTIL $3.61
- 52 Week High
- ANL $3.89
- DTIL $11.09
- Technical
- Relative Strength Index (RSI)
- ANL 44.72
- DTIL 46.19
- Support Level
- ANL $1.48
- DTIL $4.51
- Resistance Level
- ANL $1.55
- DTIL $5.12
- Average True Range (ATR)
- ANL 0.04
- DTIL 0.31
- MACD
- ANL -0.00
- DTIL 0.00
- Stochastic Oscillator
- ANL 25.00
- DTIL 35.71
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.